argenx SE (NASDAQ:ARGX) Shares Acquired by Keudell Morrison Wealth Management

Keudell Morrison Wealth Management increased its stake in shares of argenx SE (NASDAQ:ARGX) by 33.1% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 507 shares of the company’s stock after acquiring an additional 126 shares during the quarter. Keudell Morrison Wealth Management’s holdings in argenx were worth $312,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cromwell Holdings LLC increased its position in argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after purchasing an additional 66 shares during the last quarter. GAMMA Investing LLC lifted its position in argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock valued at $94,000 after buying an additional 56 shares during the last quarter. SG Americas Securities LLC boosted its stake in argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after buying an additional 21 shares during the period. Fulton Bank N.A. acquired a new stake in argenx in the 4th quarter valued at approximately $226,000. Finally, Blue Trust Inc. raised its position in argenx by 413.9% in the third quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after purchasing an additional 298 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ARGX. Robert W. Baird lowered argenx from an “outperform” rating to a “neutral” rating and increased their target price for the stock from $515.00 to $650.00 in a research note on Friday, November 1st. Baird R W lowered shares of argenx from a “strong-buy” rating to a “hold” rating in a report on Friday, November 1st. Wells Fargo & Company boosted their price target on shares of argenx from $639.00 to $723.00 and gave the stock an “overweight” rating in a research note on Thursday, December 19th. Guggenheim increased their price objective on argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Finally, JMP Securities boosted their target price on argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research note on Tuesday, January 14th. One analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, argenx currently has a consensus rating of “Moderate Buy” and an average target price of $658.39.

argenx Stock Performance

Shares of argenx stock opened at $665.68 on Friday. The company has a fifty day simple moving average of $631.59 and a 200-day simple moving average of $568.27. argenx SE has a 12-month low of $349.86 and a 12-month high of $678.21.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same quarter last year, the company posted ($1.25) earnings per share. Equities research analysts forecast that argenx SE will post 2.78 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.